Literature DB >> 17154671

Pulmonary manifestations of malaria : recognition and management.

Walter R J Taylor1, Viviam Cañon, Nicholas J White.   

Abstract

Lung involvement in malaria has been recognized for more than 200 hundred years, yet our knowledge of its pathogenesis and management is limited. Pulmonary edema is the most severe form of lung involvement. Increased alveolar capillary permeability leading to intravascular fluid loss into the lungs is the main pathophysiologic mechanism. This defines malaria as another cause of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).Pulmonary edema has been described most often in non-immune individuals with Plasmodium falciparum infections as part of a severe systemic illness or as the main feature of acute malaria. P.vivax and P.ovale have also rarely caused pulmonary edema.Clinically, patients usually present with acute breathlessness that can rapidly progress to respiratory failure either at disease presentation or, interestingly, after treatment when clinical improvement is taking place and the parasitemia is falling. Pregnant women are particularly prone to developing pulmonary edema. Optimal management of malaria-induced ALI/ARDS includes early recognition and diagnosis. Malaria must always be suspected in a returning traveler or a visitor from a malaria-endemic country with an acute febrile illness. Slide microscopy and/or the use of rapid antigen tests are standard diagnostic tools. Malaria must be treated with effective drugs, but current choices are few: e.g. parenteral artemisinins, intravenous quinine or quinidine (in the US only). A recent trial in adults has shown that intravenous artesunate reduces severe malaria mortality by a third compared with adults treated with intravenous quinine. Respiratory compromise should be managed on its merits and may require mechanical ventilation.Patients should be managed in an intensive care unit and particular attention should be paid to the energetic management of other severe malaria complications, notably coma and acute renal failure. ALI/ARDS may also be related to a coincidental bacterial sepsis that may not be clinically obvious. Clinicians should employ a low threshold for starting broad spectrum antibacterials in such patients, after taking pertinent microbiologic specimens. Despite optimal management, the prognosis of severe malaria with ARDS is poor.ALI/ARDS in pediatric malaria appears to be rare. However, falciparum malaria with severe metabolic acidosis or acute pulmonary edema may present with a clinical picture of pneumonia, i.e. with tachypnea, intercostal recession, wheeze or inspiratory crepitations. This results in diagnostic confusion and suboptimal treatment. Whilst this is increasingly being recognized in malaria-endemic countries, clinicians in temperate zones should be aware that malaria may be a possible cause of 'pneumonia' in a visiting or returning child.

Entities:  

Mesh:

Year:  2006        PMID: 17154671     DOI: 10.2165/00151829-200605060-00007

Source DB:  PubMed          Journal:  Treat Respir Med        ISSN: 1176-3450


  32 in total

1.  Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.

Authors:  Michael Hawkes; Robert Opika Opoka; Sophie Namasopo; Christopher Miller; Andrea L Conroy; Lena Serghides; Hani Kim; Nisha Thampi; W Conrad Liles; Chandy C John; Kevin C Kain
Journal:  Med Hypotheses       Date:  2011-07-13       Impact factor: 1.538

2.  What is the cause of this fever? Malaria with concomitant pneumonia.

Authors:  Blake Sterling Sanford; Laith Potrous; Maricela Castillo MacKenzie
Journal:  BMJ Case Rep       Date:  2017-11-25

3.  Clinical profile of severe malaria: study from a tertiary care center in north India.

Authors:  Shafali Nandwani; Apurva Pande; Mahip Saluja
Journal:  J Parasit Dis       Date:  2012-11-21

4.  Pulmonary pathology in pediatric cerebral malaria.

Authors:  Danny Milner; Rachel Factor; Rich Whitten; Richard A Carr; Steve Kamiza; Geraldine Pinkus; Malcolm Molyneux; Terrie Taylor
Journal:  Hum Pathol       Date:  2013-09-27       Impact factor: 3.466

5.  Plasmodium vivax infection impersonating Plasmodium falciparum malaria.

Authors:  Sweta Kakaraparthi; Raghunath Prabhu
Journal:  Eurasian J Med       Date:  2014-02

Review 6.  Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis.

Authors:  Fernando Val; Kim Machado; Lisiane Barbosa; Jorge Luis Salinas; André Machado Siqueira; Maria Graças Costa Alecrim; Hernando Del Portillo; Quique Bassat; Wuelton Marcelo Monteiro; Marcus Vinícius Guimarães Lacerda
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

7.  Enhanced expression of Fas and FasL modulates apoptosis in the lungs of severe P. falciparum malaria patients with pulmonary edema.

Authors:  Chuchard Punsawad; Parnpen Viriyavejakul; Chayanee Setthapramote; Sarawoot Palipoch
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  VEGF promotes malaria-associated acute lung injury in mice.

Authors:  Sabrina Epiphanio; Marta G Campos; Ana Pamplona; Daniel Carapau; Ana C Pena; Ricardo Ataíde; Carla A A Monteiro; Nuno Félix; Artur Costa-Silva; Claudio R F Marinho; Sérgio Dias; Maria M Mota
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

9.  Clinical and laboratory features of human Plasmodium knowlesi infection.

Authors:  Cyrus Daneshvar; Timothy M E Davis; Janet Cox-Singh; Mohammad Zakri Rafa'ee; Siti Khatijah Zakaria; Paul C S Divis; Balbir Singh
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

10.  Src-family kinase dependent disruption of endothelial barrier function by Plasmodium falciparum merozoite proteins.

Authors:  Mark R Gillrie; Gowdahalli Krishnegowda; Kristine Lee; Andre G Buret; Stephen M Robbins; S Looareesuwan; D Channe Gowda; May Ho
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.